Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer

Published:2020-05-05 Issue:13 Volume:9 Page:4756-4767
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Minnix Megan¹²,Li Lin¹,Yazaki Paul¹,Chea Junie³,Poku Erasmus³,Colcher David¹,Shively John E.¹^ORCID

Affiliation:

1. Department of Molecular Imaging and Therapy Beckman Research Institute City of Hope Duarte CA USA

2. Irell and Manella Graduate School of Biological Sciences Beckman Research Institute City of Hope Duarte CA USA

3. Radiopharmacy City of Hope Medical Center Duarte CA USA

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3078

Reference54 articles.

1. Surgical Management of Recurrent Ovarian Cancer

2. Tumor‐associated glycoprotein (TAG‐72) in Ovarian carcinomas defined by monoclonal antibody 872.3;Thor A;J Natl Can Institute,1986

3. Distribution of Tumor-Associated Glycoprotein-72 (TAG-72) Expression Throughout the Normal Female Reproductive Tract

4. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sialyl-Tn glycan epitope as a target for pancreatic cancer therapies;Frontiers in Oncology;2024-09-13

2. Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs;Journal of Controlled Release;2024-05

3. Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment;Frontiers in Drug Delivery;2024-02-01

4. CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies;Frontiers in Immunology;2023-10-03

5. Targeted drug conjugate systems for ovarian cancer chemotherapy;Biomedicine & Pharmacotherapy;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3